Exposure to Amlodipine in the First Trimester of Pregnancy and During Breastfeeding
- 1 January 2007
- journal article
- case report
- Published by Taylor & Francis Ltd in Hypertension in Pregnancy
- Vol. 26 (2), 179-187
- https://doi.org/10.1080/10641950701204554
Abstract
To assess the fetal outcome of three hypertensive women exposed to amlodipine. 5 mg/day, in the first trimester of pregnancy. CASE 1: The patient was treated with amlodipine until 7 weeks of gestation. She was also exposed to levosulpiride, aluminum hydroxide gel, magnesium carbonate, and Ginkgo biloba. At 38(+3) weeks of pregnancy, she delivered a 3750 g healthy female baby, and restarted taking amlodipine, 5 mg/day, while exclusively breastfeeding her daughter. At three months of age, the infant was healthy. CASE 2: The patient was treated with amlodipine from 2(+2) to 3(+4) weeks of pregnancy. Her treatment was modified to atenolol until the week 6(+4 weeks), when she declined any antihypertensive treatment. At 39(+4) weeks of pregnancy, the patient delivered a 2600 g baby. At 20 months old, the baby presented with intellectual delay and weakness in the left arm and hand grasp. These neurological alterations were not attributed to her exposure to amlodipine early in utero. CASE 3: The patient was treated with amlodipine from 7(+6) to 12 weeks of pregnancy. She was also taking sucralfate and lorazepam. At 12 weeks of amenorrhea, ultrasound revealed a 15.3 mm, single fetal pole in the gestational sac without cardiac activity. She underwent dilatation and evacuation of a dead embryo. As reported with other calcium-channel blockers, amlodipine does not appear to be teratogenic and it appears to be compatible with breastfeeding.Keywords
This publication has 17 references indexed in Scilit:
- Obstetric and neonatal outcomes to recombinant porcine somatotropin administered in the last third of pregnancy to primiparous sowsJournal of Endocrinology, 2006
- Major Causes of Death among Men and Women in ChinaThe New England Journal of Medicine, 2005
- Pharmacologic Treatment of Chronic Pediatric HypertensionPediatric Drugs, 2005
- Calcium channel blockers in thetreatment of hypertension and prevention of cardiovascular disease: Results from major clinical trialsClinical Cornerstone, 2004
- The VALUE trial: a commentaryJournal of the Renin-Angiotensin-Aldosterone System, 2004
- Uterine blood flow—a determinant of fetal growthEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2003
- Regulation of Fetal Growth by the Somatotrophic AxisJournal of Nutrition, 2003
- The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockersActa Obstetricia et Gynecologica Scandinavica, 2001
- The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort studyAmerican Journal of Obstetrics and Gynecology, 1996
- Digital defects induced by vasodilating agents: Relationship to reduction in uteroplacental blood flowTeratology, 1989